Novo Nordisk filed semaglutide for approval with the FDA and EMA in December. The drug suppresses appetite by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is released after eating.

The 26-week PIONEER 5 trial is one of 10 clinical trials for oral semaglutide that are due to complete this year. Novo's oral semaglutide on target in phase 3 trial | pharmaphorum Skip to main content ...

Rybelsus contains the active ingredient semaglutide. It belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist drug class. (A drug class is a group of medications that work in a similar way.) ...

Its active ingredient, semaglutide, is a synthetic version of the natural hormone GLP-1. This hormone plays a vital role in regulating blood sugar levels. You can only get Ozempic on prescription ...